Table 1.
Number of aPL antibody positive sera investigating 85 APS patients, 65 DC patients, and 79 NHS in ELISA and in the MLDA
| ELISA | MLDA | ELISA or MDLA | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| anti-CL | anti-β2 GPI | anti-CL or anti-β2 GPI | anti-PS | anti-PI | anti-CL | anti-β2 GPI | anti-PS, anti-PI, anti-CL or anti-β2 GPI | ||||||||
| IgG | IgM | IgG | IgM | IgG | IgM | IgG | IgM | IgG | IgM | IgG | IgM | ||||
| APS n = 85 |
45 | 32 | 27 | 33 | 50 | 28 | 17 | 7 | 3 | 39 | 33 | 31 | 27 | 57 | 63 |
| DC n = 65 |
1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 2 | 3 | 0 | 3 | 7 | 8 |
| NHS n = 79 |
1 | 0* | 0 | 4 | 5 | 1 | 1 | 0 | 0 | 2 | 6* | 0 | 5 | 8 | 12 |
* P < 0.05 for the comparison of ELISA and MLDA
APS, antiphospholipid syndrome; anti-β2 GPI, anti-beta2-glycoprotein I; anti-CL, anti-cardiolipin; anti-PI, anti-phosphatidylinositol; anti-PS, anti-phosphatidylserine; DC, disease controls; ELISA, enzyme-linked immunosorbent immunoassay; MLDA, multi-line dot assay; NHS, normal healthy subjects.